Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ARRY Cantor Maintains Buy On Array BioPharma As It Regains Rights To Binimetinib http://www.smarteranalyst.com/2014/12/04/cantor-maintains-buy-on-array-biopharma-as-it-regains-rights-to-binimetinib/
$ARRY Cantor Maintains Buy On Array BioPharma As It Regains Rights To Binimetinib http://www.smarteranalyst.com/2014/12/04/cantor-maintains-buy-on-array-biopharma-as-it-regains-rights-to-binimetinib/
$ANF Oppenheimer Maintains Perform On Abercrombie As Structural Challenges Persist http://www.smarteranalyst.com/2014/12/04/oppenheimer-maintains-perform-on-abercrombie-as-structural-challenges-persist/
$ANF Oppenheimer Maintains Perform On Abercrombie As Structural Challenges Persist http://www.smarteranalyst.com/2014/12/04/oppenheimer-maintains-perform-on-abercrombie-as-structural-challenges-persist/
$AGIO Agios Pharmaceuticals: We Expect Multiple Catalysts To Support The Stock, Says MLV http://www.smarteranalyst.com/2014/12/04/agios-pharmaceuticals-we-expect-multiple-catalysts-to-support-the-stock-says-mlv/
$AGIO Canaccord Sets Expectations On Agios Ahead Of ASH Annual Meeting http://www.smarteranalyst.com/2014/12/03/canaccord-sets-expectations-on-agios-ahead-of-ash-annual-meeting/
$OVTI Wedbush Cuts OmniVision Technologies Price Target Following Disappointing FQ3 Outlook http://www.smarteranalyst.com/2014/12/03/wedbush-cuts-omnivision-technologies-price-target-following-disappointing-fq3-outlook/
$MBLY William Blair Reiterates Outperform On Mobileye N.V. Following Investor Meetings With Management http://www.smarteranalyst.com/2014/12/03/william-blair-reiterates-outperform-on-mobileye-n-v-following-investor-meetings-with-management/
$PBYI Cowen Remains Positive On Puma Biotechnology In Light Of NDA Submission Delay http://www.smarteranalyst.com/2014/12/03/cowen-remains-positive-on-puma-biotechnology-in-light-of-nda-submission-delay/
$PBYI Cowen Remains Positive On Puma Biotechnology In Light Of NDA Submission Delay http://www.smarteranalyst.com/2014/12/03/cowen-remains-positive-on-puma-biotechnology-in-light-of-nda-submission-delay/
$IDRA Cowen Maintains Outperform On Shares Of Idera Following Recent Events http://www.smarteranalyst.com/2014/12/03/cowen-maintains-outperform-on-shares-of-idera-following-recent-events/
$IDRA Cowen Maintains Outperform On Shares Of Idera Following Recent Events http://www.smarteranalyst.com/2014/12/03/cowen-maintains-outperform-on-shares-of-idera-following-recent-events/
$DDD Oppenheimer Maintains Outperform On 3D Systems On The Heels Of Recent Acquisitions http://www.smarteranalyst.com/2014/12/03/oppenheimer-maintains-outperform-on-3d-systems-on-the-heels-of-recent-acquisitions/
$HAL Oppenheimer Sees The Risk/Reward In Halliburton As Favorable; Initiates Outperform http://www.smarteranalyst.com/2014/12/03/oppenheimer-sees-the-riskreward-in-halliburton-as-favorable-initiates-outperform/
$HAL Oppenheimer Sees The Risk/Reward In Halliburton As Favorable; Initiates Outperform http://www.smarteranalyst.com/2014/12/03/oppenheimer-sees-the-riskreward-in-halliburton-as-favorable-initiates-outperform/
$OVTI Oppenheimer Maintains Perform On OmniVision Technologies Following F2Q15 Results http://www.smarteranalyst.com/2014/12/03/oppenheimer-maintains-perform-on-omnivision-technologies-following-f2q15-results/
$WPRT MLV Cuts Westport Innovations Price Target Following Acquisition Of Prins Autogassystemen http://www.smarteranalyst.com/2014/12/03/mlv-cuts-westport-innovations-price-target-following-acquisition-of-prins-autogassystemen/
$BIIB Cowen Maintains Outperform On Biogen Following Phase I Results Of BIIB037 http://www.smarteranalyst.com/2014/12/03/cowen-maintains-outperform-on-biogen-following-phase-i-results-of-biib037/
$BIIB Cowen Maintains Outperform On Biogen Following Phase I Results Of BIIB037 http://www.smarteranalyst.com/2014/12/03/cowen-maintains-outperform-on-biogen-following-phase-i-results-of-biib037/
$AVNR Cowen Comments On Avanir Pharmaceuticals Following Otsuka Acquisition http://www.smarteranalyst.com/2014/12/03/cowen-comments-on-avanir-pharmaceuticals-following-otsuka-acquisition/
$AVNR Cowen Comments On Avanir Pharmaceuticals Following Otsuka Acquisition http://www.smarteranalyst.com/2014/12/03/cowen-comments-on-avanir-pharmaceuticals-following-otsuka-acquisition/
We Expect GW’s Shares To Outperform As Its Pipeline Progresses, Says Cowen http://www.smarteranalyst.com/2014/12/03/we-expect-gws-shares-to-outperform-as-its-pipeline-progresses-says-cowen/
We Expect GW’s Shares To Outperform As Its Pipeline Progresses, Says Cowen http://www.smarteranalyst.com/2014/12/03/we-expect-gws-shares-to-outperform-as-its-pipeline-progresses-says-cowen/
$CY $CODE Wedbush Raises Cypress Semiconductor Price Target Following Merger With Spansion http://www.smarteranalyst.com/2014/12/02/wedbush-raises-cypress-semiconductor-price-target-following-merger-with-spansion/
$CY $CODE Wedbush Raises Cypress Semiconductor Price Target Following Merger With Spansion http://www.smarteranalyst.com/2014/12/02/wedbush-raises-cypress-semiconductor-price-target-following-merger-with-spansion/
$CCL William Blair Sets Expectations On Carnival Corporation Ahead Of Fiscal 4Q Results http://www.smarteranalyst.com/2014/12/02/william-blair-sets-expectations-on-carnival-corporation-ahead-of-fiscal-4q-results/
$ABBV Deutsche Bank Comments On ABBV’s Humira Following Meeting With Momenta http://www.smarteranalyst.com/2014/12/02/deutsche-bank-comments-on-abbvs-humira-following-meeting-with-momenta/
Deutsche Bank Comments On ABBV’s Humira Following Meeting With Momenta
http://www.smarteranalyst.com/2014/12/02/deutsche-bank-comments-on-abbvs-humira-following-meeting-with-momenta/
$LGND Ligand Is An Attractive Financial Growth Story With Pipeline Optionality, Says Deutsche Bank http://www.smarteranalyst.com/2014/12/02/ligand-is-an-attractive-financial-growth-story-with-pipeline-optionality-says-deutsche-bank/
$LGND Ligand Is An Attractive Financial Growth Story With Pipeline Optionality, Says Deutsche Bank http://www.smarteranalyst.com/2014/12/02/ligand-is-an-attractive-financial-growth-story-with-pipeline-optionality-says-deutsche-bank/
Deutsche Bank Maintains Buy On Regeneron Following Discussion With CEO
http://www.smarteranalyst.com/2014/12/02/deutsche-bank-maintains-buy-on-regeneron-following-discussion-with-ceo/
MLV Raises Cerus Price Target As It's Gaining Traction With FDA And Blood Centers Ahead Of U.S. Approval
http://www.smarteranalyst.com/2014/12/02/mlv-raises-cerus-price-target-as-its-gaining-traction-with-fda-and-blood-centers-ahead-of-u-s-approval/
$SRPT Deutsche Bank Maintains Hold On Sarepta Therapeutics Following BioFEST Conference http://www.smarteranalyst.com/2014/12/02/deutsche-bank-maintains-hold-on-sarepta-therapeutics-following-biofest-conference/
Feltl And Company Upgrades Cypress Semiconductor As It 'Possibly Unlocked The “CODE” With Makeover Acquisition' http://www.smarteranalyst.com/2014/12/02/feltl-and-company-upgrades-cypress-semiconductor-shares-to-buy-sees-25-upside-for-the-stock/
$CY Feltl And Company Upgrades Cypress Semiconductor As It 'Possibly Unlocked The “CODE” With Makeover Acquisition' http://www.smarteranalyst.com/2014/12/02/feltl-and-company-upgrades-cypress-semiconductor-shares-to-buy-sees-25-upside-for-the-stock/
Maxim Comments On Neostem Following KOLs Presentation http://www.smarteranalyst.com/2014/12/02/maxim-comments-on-neostem-following-kols-presentation/
$NKTR Roth Capital Reiterates Buy On Nektar Therapeutics Following BAX-855 BLA Submission http://www.smarteranalyst.com/2014/12/02/roth-capital-reiterates-buy-on-nektar-therapeutics-following-bax-855-bla-submission/
$REGI Roth Capital Initiates Buy On Renewable Energy Ahead Of Positive Regulatory Catalysts http://www.smarteranalyst.com/2014/12/02/roth-capital-initiates-buy-on-renewable-energy-ahead-of-positive-regulatory-catalysts/
$VNET William Blair Reiterates Outperform On 21Vianet Following 3Q14 Financial Results http://www.smarteranalyst.com/2014/12/02/william-blair-reiterates-outperform-on-21vianet-following-3q14-financial-results/
$EXAS William Blair Maintains Outperform On Exact Sciences Following UnitedHealth Noncoverage Decision http://www.smarteranalyst.com/2014/12/02/william-blair-maintains-outperform-on-exact-sciences-following-unitedhealth-noncoverage-decision/